Journal of Clinical Oncology, Vol 25, No 32 (November 10), 2007: pp. 5063-5069
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.0197
Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions
Patricia A. Ganz,
Carolyn C. Gotay
From the University of California, Los Angeles Schools of Medicine and Public Health, Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, CA; and Cancer Research Center of Hawaii, Honolulu, HI
Address reprint requests to Patricia A. Ganz, MD, Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, 650 Charles Young Dr South, Rm A2-125 CHS, Los Angeles, CA 90095-6900; e-mail: pganz{at}ucla.edu
Purpose This article examines the challenges, opportunities, and successes that have occurred in the incorporation of patient-reported outcomes (PROs) in phase III cancer clinical trials.
Methods An informal survey of the leadership of US cooperative group PRO investigators identified diverse trials in which PROs had been measured. Exemplary trials were selected for lessons learned and for examination of successful strategies.
Results We review four challenging trials in depth, illustrating some of the difficulties in integrating PROs within treatment trials, including issues related to missing data, lack of procedures for monitoring patients and ensuring collection of PRO data, and missed opportunities in publication of treatment and PRO outcomes together. Four examples of successful trials are highlighted.
Conclusion As a result of this review, the authors make specific recommendations related to the use of PROs in phase III trials, focusing on issues related to design, choice of PRO instrument and frequency of administration, analysis, and publication strategies.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Basch, X. Jia, G. Heller, A. Barz, L. Sit, M. Fruscione, M. Appawu, A. Iasonos, T. Atkinson, S. Goldfarb, et al.
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
J Natl Cancer Inst,
November 17, 2009;
(2009)
djp386v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Mahoney, T. Bevers, E. Linos, and W. C. Willett
Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
CA Cancer J Clin,
November 3, 2008;
(2008)
CA.2008.0016v1.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W.W.M. Terstappen, K. J. Pienta, and D. Raghavan
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Clin. Cancer Res.,
October 1, 2008;
14(19):
6302 - 6309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Montgomery, E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. Kalhorn, C. S. Higano, L. D. True, and P. S. Nelson
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
Cancer Res.,
June 1, 2008;
68(11):
4447 - 4454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Moinpour, A. M. Denicoff, D. W. Bruner, A. B. Kornblith, S. R. Land, A. O'Mara, and E. Trimble
Funding Patient-Reported Outcomes in Cancer Clinical Trials
J. Clin. Oncol.,
November 10, 2007;
25(32):
5100 - 5105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lipscomb, B. B. Reeve, S. B. Clauser, J. S. Abrams, D. Watkins Bruner, L. B. Burke, A. M. Denicoff, P. A. Ganz, K. Gondek, L. M. Minasian, et al.
Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward
J. Clin. Oncol.,
November 10, 2007;
25(32):
5133 - 5140.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|